Raymond James cuts Verisk Analytics stock price target on valuation By Investing.com

Raymond James cut Verisk Analytics' price target to $230 from $260 but kept a Strong Buy rating, while raising 2027 operating EPS to $8.35 and initiating 2028 EPS at $9.10. Verisk completed a $1.5 billion accelerated share repurchase plus $126 million of open-market buybacks in Q1 2026, and Q1 EPS of $1.82 and revenue of $783 million both beat estimates. The stock trades at $170.94, near its 52-week low, but leverage remains within the 2-3x target range and the company continues to emphasize AI-related product integration.

Analysis

VRSK is behaving less like a cyclical data vendor and more like a capital-allocation compounder, which matters because the market is still pricing it with a discount typical of slower-growth software. The combination of buybacks plus a modest leverage reset should mechanically support EPS even if top-line growth stays mid-single-digit, and that creates a cleaner path for multiple recovery than many investors expect. The real second-order effect is that the company can use its subscription base as financing collateral for repurchases without taking on the kind of balance-sheet risk that usually destroys quality-premium stories.

The more interesting catalyst is not the current quarter but the next 12-24 months of estimate revision risk. If management can hold margins while layering AI-enabled workflow integration into underwriting and claims, the market may start to assign a higher growth durability premium rather than just valuing current EPS. That said, the stock’s near-low level tells you the consensus is still worried about organic growth deceleration or a structural re-rating lower, so any disappointment on renewals or integration monetization could keep it range-bound despite the balance-sheet support.

From a competitive standpoint, the AI connector strategy is more defensive than transformative in the near term: it reduces switching friction for insurers and embeds VRSK deeper into customer workflows, but it also raises expectations that rivals will match the productivity story. The contrarian view is that the buyback narrative is partly masking a slower organic growth profile; if the market stops rewarding financial engineering, the stock can stagnate even as EPS rises. Over the next few months, the cleanest tell will be whether management converts the current capital return cadence into an upward revision cycle for 2027-2028 guidance rather than just financial leverage to the per-share model.

Key Decisions for Investors

• Long VRSK on pullbacks into the low-$170s with a 6-12 month horizon; risk/reward is attractive if the market re-rates it from a low-growth compounder to a durable mid-teens EPS grower.
• Add via call spreads rather than outright stock: buy VRSK 12-18 month bull call spreads to express upside from estimate revisions while limiting downside if organic growth remains muted.
• Pair trade: long VRSK / short a higher-multiple insurance software peer basket for 3-6 months, betting VRSK’s buyback support and workflow stickiness win on relative EPS resilience.
• If VRSK breaks below the recent low on weak volume, cut exposure quickly; that would signal the market is discounting buybacks as insufficient to offset slower core growth.